Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines
- Cristina Missale*,
- Agnese Codignola†,
- Sandra Sigala,
- Alessandra Finardi,
- Marcelo Paez-Pereda‡,
- Emanuele Sher†, and
- PierFranco Spano
- Department of Biomedical Sciences and Biotechnology, Division of Pharmacology, University of Brescia, Via Valsabbina 19, 25124, Brescia, Italy; †Molecular and Cellular Pharmacology CNR Center, University of Milano, Via Vanvitelli 32, 20129 Milano, Italy; and ‡Department of Endocrinology, Clinical Institute, Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D-80804 Munchen, Germany
-
Communicated by Vittorio Erspamer, University of Rome, Rome, Italy (received for review September 10, 1997)
Abstract
Nerve growth factor (NGF) has antiproliferative and differentiating effects on adenomas of neuroendocrine origin. Cell lines derived from small-cell lung carcinoma (SCLC), a very aggressive neuroendocrine tumor, express NGF receptors. The role of NGF in the control of proliferation and progression of this carcinoma, however, has never been investigated. Chronic exposure of NCI-N-592 and GLC8 SCLC cell lines to NGF remarkably inhibited their proliferation rate both in vitro and in vivo, prevented their anchorage-independent clonal growth in soft agar, impaired their invasive capacity in vitro, and abolished their tumorigenic potential in nude mice. The proliferative response of SCLC cell lines to nicotine was also remarkably impaired by in vitro NGF treatment. Furthermore, NGF treatment activates in SCLC cell lines the expression and secretion of NGF. NGF thus reverts SCLC cell lines to a noninvasive, nontumorigenic phenotype that does not respond to nicotine and produces NGF.
Footnotes
-
↵ * To whom reprint requests should be addressed at. e-mail: cmissale{at}med.unibs.it.
- ABBREVIATIONS:
- NGF,
- nerve growth factor;
- SCLC,
- small-cell lung carcinoma;
- 5-HT,
- 5-hydroxytryptamine
- Copyright © 1998, The National Academy of Sciences
